Delving into the Latest Updates on VLP- cvD with Synapse

Overview

Basic Info

Drug Type

Virus-like particle vaccine, Prophylactic vaccine

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication-

Inactive Indication

Zika Virus Infection

Originator Organization

University of Glasgow

Active Organization-

Inactive Organization

University of Glasgow

License Organization-

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

Infection with Zika virus (ZIKV) leads to the production by the host of antibodies that target the viral surface envelope (E) protein. A subset of these antibodies can inhibit virus infection, thus making E a suitable candidate for the development of vaccine against the virus. However, the anti-ZIKV E antibodies can cross-react with the E protein of the related dengue virus on account of the high level of similarity exhibited by the two viral proteins. Such a scenario may lead to severe dengue disease. Therefore, the design of a ZIKV vaccine requires particular care. Here, we tested two candidate vaccines containing a recombinant form of the ZIKV E protein that is forced in a covalently stable dimeric conformation (cvD). They were generated with an explicit aim to reduce the exposure of the cross-reactive epitopes. One vaccine is composed of a soluble form of the E protein (sE-cvD), the other is a more complex virus-like particle (VLP-cvD). We used the two candidate vaccines to immunize mice and later infected them with ZIKV. The animals produced a high level of inhibitory antibodies and were protected from the infection. The VLP-cvD was the most effective, and we believe it represents a promising ZIKV vaccine candidate.

100 Deals associated with VLP- cvD

Login to view more data